Russell Investments Group Ltd. grew its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 96.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 778,340 shares of the company’s stock after purchasing an additional 382,371 shares during the period. Russell Investments Group Ltd. owned about 0.81% of Travere Therapeutics worth $45,829,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the business. Jupiter Topco LLC purchased a new stake in Travere Therapeutics during the second quarter worth approximately $643,299,000. Bank of America Corp DE acquired a new stake in Travere Therapeutics during the 2nd quarter worth approximately $259,527,000. Assenagon Asset Management S.A. grew its stake in shares of Travere Therapeutics by 168.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,145,414 shares of the company’s stock valued at $67,442,000 after purchasing an additional 718,109 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Travere Therapeutics by 50.0% in the 2nd quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company’s stock valued at $87,094,000 after purchasing an additional 510,808 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Travere Therapeutics in the second quarter valued at approximately $26,723,000.
Wall Street Analyst Weigh In
TVTX has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $67.00 price target on shares of Travere Therapeutics in a report on Tuesday, September 22nd. Leerink Partners lowered their price objective on shares of Travere Therapeutics from $78.00 to $67.00 and set an “outperform” rating on the stock in a research report on Thursday, November 5th. Zacks Research cut shares of Travere Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. TD Cowen upped their price objective on shares of Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Canaccord Genuity Group raised their target price on shares of Travere Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $72.55.
View Our Latest Stock Report on TVTX
Travere Therapeutics Price Performance
Shares of NASDAQ TVTX opened at $50.65 on Monday. The firm has a market capitalization of $4.86 billion, a P/E ratio of -39.26 and a beta of 1.11. Travere Therapeutics, Inc. has a one year low of $22.59 and a one year high of $68.73. The company’s fifty day moving average is $55.93 and its two-hundred day moving average is $47.55. The company has a debt-to-equity ratio of 26.72, a quick ratio of 2.95 and a current ratio of 3.00.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.49). Travere Therapeutics had a negative return on equity of 185.69% and a negative net margin of 18.66%. The company had revenue of $224.56 million for the quarter, compared to analyst estimates of $195.29 million. During the same period last year, the company earned $0.28 earnings per share. The business’s revenue for the quarter was up 36.2% compared to the same quarter last year. Analysts forecast that Travere Therapeutics, Inc. will post -0.90 EPS for the current fiscal year.
Insider Activity
In other Travere Therapeutics news, EVP Jula Inrig sold 44,674 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total transaction of $2,784,977.16. Following the transaction, the executive vice president directly owned 100,491 shares in the company, valued at approximately $6,264,608.94. This represents a 30.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Dube sold 243,735 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $53.82, for a total transaction of $13,117,817.70. Following the transaction, the chief executive officer owned 432,886 shares in the company, valued at $23,297,924.52. The trade was a 36.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,294,029 shares of company stock valued at $79,454,261 in the last quarter. Insiders own 4.44% of the company’s stock.
About Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on kidney and metabolic disorders. The company was formerly known as Retrophin and adopted the Travere Therapeutics name in 2020. Its commercial products include FILSPARI (sparsentan), an oral treatment approved in the United States for adults with primary IgA nephropathy at risk of disease progression, and THIOLA EC (tiopronin), used to help prevent cystine kidney stones in people with cystinuria.
Featured Articles
- Five stocks we like better than Travere Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding TVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report).
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
